Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Thomas Cahill
AddedMar 31, 2024
UpdatedMay 31, 2026
Thomas Cahill

Thomas Cahill

Co-Founder, Newpath Management

Crunchbase

Thomas Cahill's Career

Newpath Management
Newpath Management

Boston, MA, US

Co-Founder
Kojin Therapeutics
Kojin Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Thomas Cahill's Career

Newpath Management
Newpath Management
Investment FirmInvestment Firm62018Boston, MA, US
Co-Founder

Leadership at Newpath Management

Daniel YadegarDaniel YadegarCo-Founder

Similar to Newpath Management

New Path VenturesNew Path VenturesSanta Clara, CA, USest. 2001New Path VenturesSanta Clara, CA, US · est. 2001

NEW Path Ventures, LLC is a US-based private equity firm serving diverse clients.

Investment Firm1
Nest.Bio VentureNest.Bio VentureBoston, MA, USest. 2016Nest.Bio VentureBoston, MA, US · est. 2016

Nest.Bio Venture: A US-based life science VC firm investing in biotech, pharma, and medical research.

Investment Firm31
New England PartnersNew England PartnersBoston, MA, USNew England PartnersBoston, MA, US

New England Partners, a Boston-based private equity firm, invests in tech, healthcare, and consumer sectors, from early to late stages.

Investment Firm30
Pathway to CuresPathway to CuresNew York City, NY, USest. 2022Pathway to CuresNew York City, NY, US · est. 2022

Venture philanthropy fund investing in innovative therapies and technologies for cures.

Investment Firm3
Kojin Therapeutics
Kojin Therapeutics
Series A$60M252020Cambridge, MA, US
Board Member· Board

Leadership at Kojin Therapeutics

Vasanthi ViswanathanVasanthi ViswanathanCo-Founder
Gini DeshpandeGini DeshpandeBoard Member
Benjamin CravattBenjamin CravattCo-Founder
Amir NashatAmir NashatBoard Member
Luba GreenwoodLuba GreenwoodBoard Member
Stuart SchreiberStuart SchreiberCo-Founder

Similar to Kojin Therapeutics

Kovina TherapeuticsKovina TherapeuticsIndianapolis, IN, USAntiviral Therapeuticsest. 2020Kovina TherapeuticsIndianapolis, IN, US · est. 2020

Kovina Therapeutics: A preclinical biotech firm developing first-in-class antiviral therapies for HPV-related conditions.

Angel · $2.6M5
Kymera TherapeuticsKymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167
Z SquaredZ SquaredWexford, PA, USPharmaceuticalsest. 1996Z SquaredWexford, PA, US · est. 1996

Coeptis Therapeutics: Developing and acquiring pharmaceutical products through strategic partnerships.

Public · $11M10
Kinaset TherapeuticsKinaset TherapeuticsMedfield, MA, USRespiratory Drugsest. 2020Kinaset TherapeuticsMedfield, MA, US · est. 2020

Kinaset Therapeutics develops novel respiratory drugs to address unmet medical needs.

Series A · $41.5M11

Thomas Cahill's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Thomas Cahill

Michel SadelainMichel SadelainCo-Founder · Juno TherapeuticsDamian DupuyDamian DupuyFounder · TheromicsStanley FrankelStanley FrankelBoard Member · ImmunaiBrian FiskeBrian FiskeBoard Member · Alix VenturesLaura TowartLaura TowartCo-Founder · CelmatixAlexander Sasha KambAlexander Sasha KambCo-Founder · A2 Biotherapeutics